文献速递神经肿瘤

高级别胶质瘤MRI与FET-PET/MRI靶区体积差异的前瞻性初步研究

Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT).
PubMed 文献 · J Neurooncol · 2026-10-14

FETSMaRT前瞻性纳入30例WHO 3或4级高级别胶质瘤术后放疗患者,放疗医师对PET设盲,回顾性量化MRI与FET-PET/MRI衍生靶区体积差异。FET-PET/MRI的GTV、CTV、PTV均显著大于MRI体积,提示解剖MRI系统性低估代谢活跃肿瘤范围;胶质母细胞瘤亚组中GTV与CTV差异较大者至进展时间数值上更短但未达统计学显著。

要点

  • FET-PET/MRI衍生GTV、CTV、PTV均显著大于MRI基于解剖的靶区体积。
  • GTV差异见于56.7%患者,CTV差异见于50.0%患者,提示系统性低估。
  • 胶质母细胞瘤亚组中GTV/CTV差异与至进展时间关联未达统计学显著。

核心结论

  • FET-PET/MRI衍生靶区体积显著大于MRI基于解剖的靶区体积,证实解剖MRI系统性低估代谢活跃肿瘤范围。
  • 本初步研究中GTV与CTV差异方向性提示可能与进展相关但未达统计学显著,属假设生成性数据。

研究设计与样本

  • FETSMaRT为前瞻性初步研究,纳入30例WHO 3或4级高级别胶质瘤接受术后放疗患者。
  • 放疗前采集FET-PET/MRI,放疗医师对PET设盲,回顾性量化MRI与FET-PET/MRI衍生GTV、CTV、PTV体积差异。
  • 胶质母细胞瘤亚组(n=23)采用Kaplan-Meier与Cox分析GTV及CTV差异与至进展时间的关系。

主要发现

  • 中位年龄60岁,77%为胶质母细胞瘤,60%存在MGMT启动子甲基化。
  • GTV差异见于17/30例(56.7%),CTV差异见于15/30例(50.0%)。
  • FET-PET/MRI衍生体积显著大于MRI体积:GTV 43.6 vs. 38.6 cc(p < 0.0001),CTV 119.2 vs. 110.8 cc(p = 0.0045),PTV 171.1 vs. 159.6 cc(p = 0.0003)。
  • GTV∆与CTV∆较大者中位至进展时间数值上更短,但均未达统计学显著。
  • 放疗失败以中心性为主(60.0%)。

临床怎么用

  • 在高级别胶质瘤放疗靶区勾画中,应意识到解剖MRI可能系统性低估代谢活跃肿瘤范围。
  • FET-PET/MRI可提供补充信息以识别MRI靶区外代谢活跃浸润,但本初步研究尚未证实其改善进展结局。
  • 研究结果为假设生成性,支持开展FET-PET引导放疗的前瞻性试验。

局限性

  • 为初步研究,样本量30例,胶质母细胞瘤亚组23例。
  • GTV与CTV差异和至进展时间的关联未达统计学显著。
  • 为单中心前瞻性初步研究,FET-PET/MRI整合放疗规划的证据仍需更大规模前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-grade gliomas carry a poor prognosis, and MRI-based radiotherapy (RT) planning may inadequately capture metabolically active tumor infiltration. ¹⁸F-fluoroethyl-tyrosine (FET) PET provides superior tumor delineation, yet prospective North American evidence supporting integration with RT planning remains limited. METHODS: FETSMaRT enrolled 30 patients with WHO grade 3 or 4 high-grade glioma receiving post-operative RT. FET-PET/MRI was acquired before RT with the radiation oncologist blinded to PET, enabling retrospective quantification of discordance between MRI-based and FET-PET/MRI-derived gross tumor (GTV), clinical target (CTV), and planning target (PTV) volumes. In the glioblastoma subgroup (n = 23), Kaplan-Meier and Cox analyses related GTV and CTV discordance to time to progression. RESULTS: Median age was 60 years; 77% had glioblastoma and 60% MGMT promoter methylation. GTV discordance occurred in 17/30 patients (56.7%) and CTV discordance in 15/30 (50.0%). FET-PET/MRI-derived volumes significantly exceeded MRI-based volumes for GTV (43.6 vs. 38.6 cc; p < 0.0001), CTV (119.2 vs. 110.8 cc; p = 0.0045), and PTV (171.1 vs. 159.6 cc; p = 0.0003). Larger GTV∆ and CTV∆ change values were associated with numerically shorter median time to progression, but neither association was statistically significant. Radiation treatment failures were predominantly central (60.0%). CONCLUSION: FET-PET/MRI-derived target volumes were significantly larger than MRI-based volumes, confirming systematic underestimation of metabolically active tumor extent by anatomical MRI. While not meeting significance in this pilot study, directional CTV and GTV discordance suggests a possible association with progression; the hypothesis generating exploratory pilot data nonetheless justify a prospective trial of FET-PET-guided RT in high-grade glioma. NCT06499831.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Singnurkar A, Sahgal A, Lechtman E, et al. Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT). J Neurooncol. 2026. PMID: 42875659. doi:10.1007/s11060-026-05831-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。